US/UK/Canada

Share

Contacts

  • Visiting address
    Salipro Biotech AB Teknikringen 38A 114 28 Stockholm Sweden

    • Links

    Pick a time period -
    Tags ( Active)

    Salipro Biotech Expands Global Intellectual Property Portfolio with Granted Patents in Australia and Singapore

    Salipro Biotech strengthens its global intellectual property portfolio with granted patents in Singapore and Australia, protecting its proprietary Salipro[®] platform technology to enable the development of therapeutics against challenging drug targets.Stockholm, Sweden, December 5, 2024 – Salipro Biotech AB, a Swedish biotechnology company focused on advancing drug discovery for challenging drug targets, today announced the issuance of granted patents in both Singapore and Australia for its Salipro[®] platform technology, a novel and proprietary method for directly isolating and purifying

    Salipro Biotech Obtains Grant for Key Patent from the European Patent Office

    This additional European patent will further strengthen Salipro Biotech’s integrated IP portfolio protecting its proprietary Salipro[®] platform technology to stabilize challenging drug targets and enable the discovery and development of next-generation therapeutics.Stockholm, Sweden, March 14, 2024 – Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech’s growing patent portfolio:

    Salipro Biotech and Icosagen Launch Antibody Discovery Collaboration

    Salipro Biotech and Icosagen announce the initiation of a multi-target collaboration for the discovery and characterization of monoclonal antibodies against several GPCRs and SLC transporters.Stockholm, Sweden and Tartu, Estonia, October 10, 2023 – Swedish biotech company Salipro Biotech AB and Estonian biotechnology company Icosagen today announced that they entered into a multi-target antibody research agreement to advance drug discovery programs against several challenging membrane proteins, including G protein-coupled receptors (GPCRs) and solute carrier (SLC) transporters. The

    Salipro Biotech enters into research collaboration with Sumitomo Pharma to advance a drug discovery program

    The collaboration leverages Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilize a challenging drug target to investigate the pharmacological characteristics of a compound from Sumitomo Pharma’s discovery program.Stockholm, Sweden, September 12, 2023 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Sumitomo Pharma Co., Ltd. to reveal the mechanism of action and pharmacological characterization of a drug candidate. Under the terms of the collaboration, Salipro Biotech will utilize its unique

    Salipro Biotech Expands Global Intellectual Property Portfolio with Granted Patent in Japan

    Salipro Biotech obtains granted patent in Japan, protecting its proprietary Salipro® platform technology to enable the development of therapeutics against challenging drug targets, including GPCRs, SLCs and Ion Channels.Stockholm, Sweden, June 13, 2023 – Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, is delighted to announce the issuance of a new patent in Japan for its Salipro® platform technology. The patent, entitled "Saposin lipoprotein particles and libraries from crude membranes", (Japanese

    Salipro Biotech and DyNAbind Announce Milestone Achievement in Collaboration to Enable DEL for Membrane Proteins

    The two biotech companies report that they have successfully screened and identified several small molecule compounds that bind to a challenging membrane protein drug target.Stockholm, Sweden and Dresden, Germany, May 9, 2023- Salipro Biotech AB and DyNAbind GmbH, two leading biotech companies, announced today the achievement of a key milestone from their collaboration aimed to revolutionize drug discovery against difficult-to-drug targets. The collaboration combines the benefits of Salipro Biotech’s proprietary platform technology for membrane proteins with DyNAbind’s proprietary DNA-

    Salipro Biotech enters into collaboration and license agreement with Sanofi to advance discovery programs

    The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilize a challenging drug target with Sanofi’s drug discovery programs to move forward the generation of biologicsStockholm, Sweden, November 8, 2022 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target. The collaboration brings together Salipro Biotech’s unique expertise in developing stable antigens of GPCRs, ion

    Salipro Biotech Obtains Granted Patents in the United States and China for Direct Extraction of Membrane Proteins and Library Generation

    Salipro Biotech strengthens its IP portfolio protecting its innovative, proprietary technology to enable the development of therapeutics against challenging drug targets, including GPCR’s, SLCs and Ion Channels.Stockholm, Sweden, September 07, 2022. – Salipro Biotech AB, a Swedish biotech company with a leading technology platform for the stabilization of membrane proteins for drug development, announced today that its patent entitled “Saposin lipoprotein particles and libraries from crude membranes” has been issued by both the U.S. Patent and Trademark Office (U.S. Patent No. 11,346,843B2)

    Salipro Biotech Receives European Patent for Antigen production

    Approvals in this patent family both in Europe as well as in the US further strengthen Salipro Biotech’s proprietary platform technologies to enable drug discovery programs for therapeutic antibodies against challenging drug targets.Stockholm, Sweden, February 8, 2022 – Swedish biotech company Salipro Biotech AB today announced that the European Patent Office has granted a further European Patent to the company, No. EP 3 043 814 B1 entitled “Antigen and method for production thereof”, following the approval of the US-member of this patent family already in 2018 under US Patent 10,159,729 B2.

    Salipro Biotech enters into a collaboration and license agreement with AbCellera

    Salipro Biotech enters into a collaboration and license agreement with AbCellera for access to the Salipro® Platform for antibody discovery against GPCRs, ion channels, and transporters The collaboration enables AbCellera to access Salipro Biotech’s unique expertise and its Salipro® platform technology to generate stable antigens for challenging membrane protein drug targets for antibody discovery.Stockholm, Sweden, October 12, 2021 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a collaboration and licensing agreement with AbCellera for access to

    Salipro Biotech Awarded European Patent for Direct Extraction of Membrane Proteins and Library Generation

    Salipro® platform technology strengthened to accelerate discovery programs for therapeutic antibodies and small molecule drugs against challenging drug targetsStockholm, Sweden, February 17, 2021 –Swedish biotech company Salipro Biotech AB today announced that the European Patent Office has issued the European Patent No. 3463303, titled “Saposin lipoprotein particles and libraries from crude membranes”. The patent covers the company’s novel method of direct extraction of membrane proteins (DirectMX™) from cells or crude membranes to enable drug development for challenging drug targets, as

    Salipro Biotech and DyNAbind enter collaboration agreement

    Stockholm, Sweden / Dresden, Germany, 09 November 2020 – Salipro Biotech AB and DyNAbind GmbH are teaming up to tackle drug discovery against challenging membrane protein targets! By bringing together Salipro’s proprietary membrane stabilizing platform technology with DyNAbind’s proprietary DNA-Encoded Library (DEL) technologies, the teams aim to accelerate the development of novel drugs for these contemporary targets. Jens Frauenfeld, co-founder and CEO of Salipro Biotech AB: “We are excited to develop novel hits for challenging drug targets such as GPCR and Ion Channels with DyNAbind.

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe